Revenio: A 48% Sales Jump That Hides a Much Messier Business

On September 8, 2026, Revenio's shares fell roughly 17% on the day. The number that looked scary was also the number that looked good, and understanding why both were true is the whole story.

In its half-year report for the first six months of 2026, the Finnish maker of iCare eye-pressure screening devices said second-quarter net sales jumped 48.1% to EUR 39.3 million, from EUR 26.5 million a year earlier. That is a strong growth figure by any standard. But the growth came almost entirely from one month of a company it just bought, and the underlying margin on each euro of sales came down hard. The stock was repricing what Revenio actually is now, not the growth number on the top line.

The +48% is inorganic; the real business was flat

The single fact that reframes the quarter is this: Revenio began counting its Visionix acquisition in its results on June 1, 2026. That is one month of revenue. Management told analysts on the earnings call that, without Visionix, the legacy iCare business was flat. The 48% was not demand accelerating; it was an accounting boundary.

For context, this is the same iCare business that delivered a genuinely solid 2025: net sales of EUR 109.7 million, up 9.1% at constant currency, with a 24.2% adjusted operating margin and EUR 30.2 million of operating cash flow. That was a profitable, cash-generating company with a near-debt-free balance sheet (an equity ratio of about 76%). On paper, it was not a company in trouble.

The 48% headline, then, is a merger artifact, and reading it as organic momentum would be a mistake. The question the market is actually answering is what happened to the economics underneath.

The margin fell, and part of that is structural

Gross margin — the share of each sales euro that remains after the direct cost of making the product, before overhead and interest — is the most important number here. In the second quarter of 2026 it fell to 64.7%, from 72.6% in the same quarter of 2025. That is a drop of 7.9 percentage points on the money that funds everything else.

Management attributed the slide to three drivers, and they are not all the same kind of problem. Visionix is a lower-margin business than iCare, so mixing it in mechanically pulls the combined margin down — that piece is structural and likely to persist. Tariffs and rising component costs are more cyclical, and management pointed to some recovery from the prior quarter. A shift toward fundus-imaging hardware also weighed on the mix. Adjusted operating margin — the profit after overhead but before one-time costs — fell to 14.6% in the quarter, from 24.7% a year earlier. Stripping out about EUR 3.4 million of one-off acquisition costs does not restore the old profitability; the business is structurally less profitable than it was twelve months ago.

That is the honest core of the story. Revenio is no longer the high-margin, slow-but-steady iCare business. It is a bigger, cheaper-margin, more-levered company that has to make integration work to justify the change.

The deal also changed the balance sheet

The €290 million Visionix purchase was financed largely with new debt and shares, and the result is a balance sheet that bears little resemblance to the 2025 one. Net debt rose to about EUR 238 million at the end of June, from essentially zero the year before. Measured against pro forma 2025 earnings, net debt stood at about 5.3 times adjusted EBITDA, and net gearing — net debt relative to equity — jumped from near nothing to roughly 160%, while the equity ratio fell to 31%. Operating cash flow turned negative, at EUR -5.8 million for the half against EUR +11.4 million a year earlier.

Revenio's plan is an approximately EUR 80 million rights issue in the second half to bring net debt/EBITDA back down toward around 3 times. For a small-cap that is a meaningful dilution, but it is also the standard fix for exactly this situation. The point is not that this is fatal; it is that the safety margin that made the pre-deal company attractive has been consumed, and the company now has more debt to service and a dilution to run through shareholders.

What the bulls point to

It would be incomplete to stop at the damage. The argument for the deal is scale and synergy. Adjusted for the Visionix acquisition, 2025 sales would have been roughly EUR 252.5 million with about EUR 45.0 million of adjusted EBITDA, and the deal expands the addressable market about 2.5-fold into optical coherence tomography (OCT), a fast-growing imaging category. By mid-2026 management had secured EUR 5 million of run-rate synergy, toward a target of more than EUR 20 million. Its long-term targets are 25% EBITDA margin in 2028–2029 and an approach to 30% beyond that, growing about three times the market. If the combined company gets there, this mess is the entry point to a bigger, still-high-margin business.

The catch is that the proof has to show up. Revenio withdrew its original 2026 guidance and replaced it with FX-adjusted net sales of EUR 190–205 million for the full year and profitability that it described only as a "satisfactory level" — vaguer, not firmer, than what it had offered in February. A Capital Markets Day is set for September 15, 2026, where management will be expected to show the integration roadmap and the 2027–2030 targets in enough detail to be testable.

The read

The stock fell, but the business also genuinely got less clean: lower margins, heavy debt, negative cash flow, and a legacy business that was not even growing before the deal. The discount therefore reflects real impairment, not just fear, which means a cheaper price does not automatically compensate for it.

The valuation bridge to a buy is visible progress, not today's numbers: synergy delivery, integration milestones, a credible path back toward the 25%+ EBITDA margin, and a rights issue that runs cleanly. Until those show up, this is too early to call the decline a bargain. The 48% growth number was real, and it was also the least of what changed.